Brigham and Women's Hospital
Boston, MA
Not yet accepting
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- CD3
- Phase 1
Not yet accepting
Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Monoclonal Antibody
- SLAMF7
- Phase 1/2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Light Chain Cast Nephropathy in Myeloma Patients
The Effect of Novel Treatments in Improving Renal Outcomes Among Patients With Light Chain Cast Nephropathy
Accepting patients
Acute Kidney Injury in Myeloma Patients
Biomarkers of AKI in Patients with Multiple Myeloma Receiving Daratumumab: a Pilot Study
1 hidden based on your filters. Show All